SCHEMBL17101486

SCHEMBL17101486

O=C1NC(Cc2ccccn2)C2(CCN(Cc3ccccc3)CC2)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 3/20 0.46
OPRM1 P35372 2/20 0.46
OPRD1 P41143 2/20 0.46
OPRK1 P41145 2/20 0.46
SIGMAR1 Q99720 5/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHRM2 P08172 1/20 0.42
EGLN1 Q9GZT9 2/20 0.41
CYP3A4 P08684 1/20 0.40
HSD17B10 Q99714 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18075896 0.86 SIGMAR1 (0.48) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL29822545 0.81 SMN1; SMN2 (0.37) OPRL1OPRM1OPRD1OPRK1KDM4E
SCHEMBL17101501 0.81 SMN1; SMN2 (0.37) OPRL1OPRM1OPRD1OPRK1KDM4E
SCHEMBL17101341 0.79 SIGMAR1 (0.45) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL23289886 0.77 TRPV6 (0.35) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL17113644 0.76 OPRM1 (0.50) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL17101500 0.72 L3MBTL1 (0.32) KDM4ESMN1; SMN2ALDH1A1
SCHEMBL17101275 0.72 CHRM1 (0.41) OPRD1KDM4ECHRM2ALDH1A1
SCHEMBL13864847 0.71 OPRL1 (0.48) OPRL1OPRM1OPRD1OPRK1SIGMAR1
SCHEMBL22653213 0.71 OPRD1 (0.31) OPRD1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202843-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2025-01-21 US disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 US disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 US disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 EP disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 EP disclosed
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
CN-107406449-B Spiro compounds as agonists of the muscarinic M1 receptor and/or M4 receptor 赫普泰雅治疗有限公司 2020-11-10 CN disclosed
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2018-03-15 US disclosed
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2018-03-15 US disclosed
EP-3271358-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR Heptares Therapeutics Limited (GB) 2018-01-24 EP disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
EP-3119396-A1 MUSCARINIC RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2017-01-25 EP disclosed
WO-2016147011-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LIMITED (GB) 2016-09-22 WO disclosed
WO-2016147011-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LIMITED (GB) 2016-09-22 WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 OPRL1 48/4885OPRM1 33/4885OPRD1 86/4885
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 OPRL1 48/4885OPRM1 34/4885OPRD1 87/4885
US-12202843-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 OPRL1 48/4885OPRM1 34/4885OPRD1 87/4885
US-11034704-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 OPRL1 48/4885OPRM1 34/4885OPRD1 87/4885
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR CHRM1, CHRM2, CHRM4 OPRL1 95/4885OPRM1 59/4885OPRD1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.